Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
Breast cancer
ERα
ESR1
GATA3
Luminal subtypes
Menin
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
02
03
2021
accepted:
26
07
2021
pubmed:
26
9
2021
medline:
3
11
2021
entrez:
25
9
2021
Statut:
ppublish
Résumé
Menin, encoded by the MEN1 gene, was recently reported to be involved in breast cancers, though the underlying mechanisms remain elusive. In the current study, we sought to further determine its role in mammary cells. Menin expression in mammary lesions from mammary-specific Men1 mutant mice was detected using immunofluorescence staining. RT-qPCR and western blot were performed to determine the role of menin in ERα expression in human breast cancer cell lines. ChIP-qPCR and reporter gene assays were carried out to dissect the action of menin on the proximal ESR1 promoter. Menin expression in female patients with breast cancer was analyzed and its correlation with breast cancer subtypes was investigated. Immunofluorescence staining revealed that early mammary neoplasia in Men1 mutant mice displayed weak ERα expression. Furthermore, MEN1 silencing led to both reduced ESR1 mRNA and ERα protein expression in MCF7 and T47D cells. To further dissect the regulation of ESR1 transcription by menin, we examined whether and in which way menin could regulate the proximal ESR1 promoter, which has not been fully explored. Using ChIP analysis and reporter gene assays covering - 2500 bp to + 2000 bp of the TSS position, we showed that the activity of the proximal ESR1 promoter was markedly reduced upon menin downregulation independently of H3K4me3 status. Importantly, by analyzing the expression of menin in 354 human breast cancers, we found that a lower expression was associated with ER-negative breast cancer (P = 0.041). Moreover, among the 294 ER-positive breast cancer samples, reduced menin expression was not only associated with larger tumors (P = 0.01) and higher SBR grades (P = 0.005) but also with the luminal B-like breast cancer subtype (P = 0.006). Consistent with our clinical data, we demonstrated that GATA3 and FOXA1, co-factors in ESR1 regulation, interact physically with menin in MCF7 cells, and MEN1 knockdown led to altered protein expression of GATA3, the latter being a known marker of the luminal A subtype, in MCF7 cells. Taken together, our data provide clues to the important role of menin in ERα regulation and the formation of breast cancer subtypes.
Identifiants
pubmed: 34561764
doi: 10.1007/s10549-021-06339-9
pii: 10.1007/s10549-021-06339-9
pmc: PMC8558183
doi:
Substances chimiques
ESR1 protein, human
0
Esr1 protein, mouse
0
Estrogen Receptor alpha
0
Hepatocyte Nuclear Factor 3-alpha
0
MEN1 protein, human
0
Men1 protein, mouse
0
Proto-Oncogene Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
389-401Subventions
Organisme : Epigenetics & Cancer Program
ID : ASC14092CSA
Organisme : Fondation de l'Association pour la Recherche contre le Cancer
ID : SFI20101201530
Organisme : the Ligue Inter-régionale contre le Cancer
ID : R19040CC
Organisme : Région Auvergne-Rhône-Alpes
ID : SICORRA22425
Informations de copyright
© 2021. The Author(s).
Références
Breast Cancer Res Treat. 2010 Jul;122(2):395-407
pubmed: 19847644
PLoS Genet. 2016 Sep 02;12(9):e1006279
pubmed: 27588951
Mol Endocrinol. 2003 Sep;17(9):1880-92
pubmed: 12819299
J Breast Health. 2015 Apr 1;11(2):59-66
pubmed: 28331693
J Pathol. 2017 May;242(1):90-101
pubmed: 28188614
Oncol Lett. 2014 Jul;8(1):230-234
pubmed: 24959251
Oncogene. 2019 May;38(21):4015-4027
pubmed: 30692633
Mol Endocrinol. 2001 Dec;15(12):2057-63
pubmed: 11731608
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Cancer Res. 2007 Jul 1;67(13):6477-83
pubmed: 17616709
Blood. 2010 Aug 26;116(8):1280-90
pubmed: 20484083
Cell Biochem Biophys. 2015 Jun;72(2):333-8
pubmed: 25543329
Nature. 2012 Feb 12;482(7386):542-6
pubmed: 22327296
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Mol Cell Biol. 2004 Jul;24(13):5639-49
pubmed: 15199122
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Genet Med. 2009 Dec;11(12):825-35
pubmed: 19904212
Cancer Res. 2006 May 1;66(9):4929-35
pubmed: 16651450
Cell Death Differ. 2017 Apr;24(4):672-682
pubmed: 28106886
Am J Cancer Res. 2015 Sep 15;5(10):2929-43
pubmed: 26693050
Nat Med. 2015 Apr;21(4):344-52
pubmed: 25822367
N Engl J Med. 2014 Aug 7;371(6):583-4
pubmed: 25099597
J Biol Chem. 2004 Sep 24;279(39):40267-75
pubmed: 15150273
J Clin Endocrinol Metab. 1998 Aug;83(8):2617-20
pubmed: 9709920
Cell Rep. 2017 Mar 7;18(10):2359-2372
pubmed: 28273452
J Pathol. 2013 Mar;229(4):546-58
pubmed: 23180448
Biomark Cancer. 2013 Oct 29;5:61-70
pubmed: 24250234
Trends Biochem Sci. 2013 Aug;38(8):394-402
pubmed: 23850066
Am J Cancer Res. 2019 Aug 01;9(8):1682-1694
pubmed: 31497350
Biologics. 2012;6:289-97
pubmed: 22956860